Business development in clinical research operates differently than in almost any other industry. Sales cycles stretch across months or years, decision-making involves multiple stakeholders across sponsor, CRO, and site organizations, and relationships built years earlier frequently determine which sites get allocated new studies today. For business development professionals working the sponsor-CRO-site triangle, understanding how these relationships actually function, beyond the formal RFP process, is often the difference between a growing pipeline and a stagnant one.
Understanding the Three-Sided Relationship
Clinical trial business development rarely happens in a simple two-party transaction. Sponsors (typically pharmaceutical or biotech companies) fund and own the studies. CROs (contract research organizations) are frequently hired by sponsors to manage study execution, including site selection and monitoring. Research sites deliver the actual patient enrollment and data collection. A site's business development strategy has to account for all three relationships simultaneously, because a study opportunity can originate from any of them.
Direct Sponsor Relationships
Some sponsors, particularly mid-size and specialty pharma companies, manage site relationships directly without a CRO intermediary for at least a portion of their portfolio. These relationships tend to be the most durable once established, because the sponsor's clinical operations team develops direct familiarity with a site's performance across multiple studies over time.
CRO-Mediated Relationships
The majority of large pharma studies flow through CROs, who maintain their own preferred site networks and manage the feasibility, selection, and monitoring process on the sponsor's behalf. Building relationships with CRO feasibility and site management teams, not just individual study CRAs, is essential because CROs frequently recommend the same trusted sites across multiple sponsor programs.
Site Management Organizations and Networks
An increasing share of study allocation flows through formal site networks and SMOs that aggregate multiple individual sites under a single business development and operational umbrella, giving sponsors a single point of contact for a broader geographic and patient-population footprint.
What Actually Drives Study Allocation Decisions
Beyond the formal feasibility scoring process, several relationship-driven factors consistently influence which sites get selected for new studies:
Track Record with Specific CRAs and CRO Teams
Individual clinical research associates and CRO feasibility managers develop working relationships with sites over time, and their internal recommendations carry significant weight even within a formally structured selection process. A site that has consistently delivered clean data and met enrollment timelines on prior studies with a specific CRA becomes that CRA's default recommendation for future opportunities in their portfolio.
Responsiveness and Ease of Doing Business
Sponsors and CROs managing dozens of site relationships simultaneously place real value on sites that are easy to work with: fast feasibility survey turnaround, responsive communication, and efficient contract negotiation. Sites with a reputation for being difficult or slow to engage lose allocation opportunities even when their clinical capability is strong.
Existing Master Agreements and CDAs
Sites with pre-executed confidentiality disclosure agreements (CDAs) and master clinical trial agreements (MCTAs) in place with a sponsor or CRO reduce startup timeline risk significantly, which is itself a meaningful selection factor when programs are under time pressure.
Warm Introductions and Industry Relationships
Despite the formalization of feasibility and selection processes, personal relationships and warm introductions, through conferences, prior colleagues who've moved between sponsor and CRO organizations, and direct networking, remain one of the highest-converting channels for surfacing new study opportunities before they're broadly circulated.
Building a Sustainable BD Pipeline in Clinical Research
Conference and Industry Event Strategy
Major conferences (ADA, ADLM, SCRS, DIA, and therapeutic-area-specific meetings) remain central to relationship-building in this industry, but attending alone doesn't generate pipeline. Effective conference strategy requires pre-planning targeted meetings with specific sponsor and CRO contacts, and disciplined post-conference follow-up, personalized outreach within days of the event, not weeks, consistently outperforms generic mass follow-up emails.
CRM Discipline and Pipeline Tracking
Clinical research BD cycles are long enough that opportunities and contacts get lost without disciplined tracking. Maintaining a structured pipeline, by sponsor, CRO, contact, study stage, and next action, prevents warm relationships from going cold simply due to lack of follow-up cadence.
Feasibility Response Quality and Speed
As covered in site selection strategy broadly, feasibility survey responsiveness is itself a competitive differentiator. BD teams that build templated, rapidly customizable feasibility response processes consistently convert more survey opportunities into actual study allocations.
Therapeutic Area Specialization
Sites and BD teams that build a clear, demonstrable specialization, in a specific therapeutic area, patient population, or study phase, are easier for sponsors and CROs to remember and recommend than generalist sites competing on breadth alone. A site known specifically for strong diabetes or dermatology enrollment becomes a go-to recommendation within that specific niche.
Leveraging Existing Industry Relationships
In an industry where personal reputation and prior working relationships carry significant weight, warm introductions from established industry contacts, former colleagues now at sponsor or CRO organizations, or advisors with deep sponsor relationships, remain disproportionately effective compared to cold outreach alone.
Common BD Mistakes in Clinical Research
- Treating every sponsor conversation as a cold pitch rather than researching the sponsor's current pipeline and therapeutic focus areas before reaching out.
- Overpromising on enrollment projections to win a study, which damages the relationship and future allocation opportunities when the site inevitably underperforms against the inflated projection.
- Neglecting CRO relationships in favor of direct sponsor outreach only, missing the majority of study opportunities that flow through CRO-managed feasibility processes.
- Inconsistent follow-up cadence, letting promising early conversations go cold due to lack of a disciplined pipeline management process.
- Underinvesting in post-conference follow-up, treating attendance itself as the deliverable rather than the deliberate relationship-building work that happens in the weeks after.
Market Trends Reshaping Clinical Research BD
- Site network consolidation is shifting BD relationships toward network-level conversations rather than individual site pitches, requiring BD teams to think and position at a portfolio level.
- Increased sponsor emphasis on data-backed capability claims over general capability statements, pushing BD teams to build genuine performance dashboards rather than relying on qualitative pitches alone.
- Growing role of embedded and community-based site networks as sponsors seek broader, more diverse patient access than traditional academic-medical-center-centric site networks can provide.
- CRO market consolidation through mergers and acquisitions is concentrating study allocation decisions among a smaller number of larger CRO organizations, making relationship depth with fewer, larger CRO partners increasingly valuable.
Practical Takeaways
Successful business development in clinical research requires operating simultaneously across sponsor, CRO, and site relationships, with disciplined pipeline management, fast and high-quality feasibility responses, and a clear, demonstrable specialization that makes a site or network memorable and recommendable. Relationships built over years, not transactional single-study pitches, remain the foundation of sustainable growth in this industry.
If you're building out a BD strategy for a research site network, or looking to strengthen sponsor and CRO relationships, it's worth a direct conversation about what's actually converting in today's market.
Want to talk through your business development strategy or explore a partnership opportunity? Book a quick chat with Kevin here.
